Tihomir Tomašič

University of Ljubljana — SI

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index3.8kcitations175works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(44), Bioactive Compounds and Antitumor Agents(22), Antibiotic Resistance in Bacteria(20), Glycosylation and Glycoproteins Research(20), Synthesis and biological activity(18)

Publications175 total

New mitochondrial KV1.3 conjugates are potent and specific inducers of apoptosis in cancer models
Biomedicine & Pharmacotherapy·2026Open Access
Inactive ryanodine receptors sustain lysosomal availability for autophagy by promoting ER-lysosomal contact site formation
Nature Communications·2026Open Access
Lipophilic cations as mitochondria-targeting moieties
Repository of the University of Ljubljana (University of Ljubljana)·2025Open Access
Lipophilic Cations as Mitochondria-Targeting Moieties: Recent Progress and Design Principles for Medicinal Chemistry
Journal of Medicinal Chemistry·2025· 1 citedOpen Access
Targeting voltage-gated proton channel HV1: Optimised 5-phenyl-2-aminoimidazoles with anticancer potential
European Journal of Medicinal Chemistry·2025Open Access
Exploration of the chemical space of benzamide-based voltage-gated potassium channel K <sub>v</sub> 1.3 inhibitors
Acta Pharmaceutica·2025Open Access
Author Correction: Nanomolar inhibitor of the galectin-8 N-terminal domain binds via a non-canonical cation-π interaction
Communications Chemistry·2025· 1 citedOpen Access
Nanomolar inhibitor of the galectin-8 N-terminal domain binds via a non-canonical cation-π interaction
Communications Chemistry·2025· 3 citedOpen Access
New Inhibitors of β‐1,4‐Galactosyltransferase I Discovered by Virtual Screening
ChemMedChem·2024· 2 citedOpen Access
Correction to “Identification of a Novel Structural Class of HV1 Inhibitors by Structure-Based Virtual Screening”
Journal of Chemical Information and Modeling·2024Open Access
Inactive ryanodine receptors sustain lysosomal availability for autophagy by promoting ER-lysosomal contact site formation
2024· 1 citedOpen Access
Unveiling the antiglioblastoma potential of harmicens, harmine and ferrocene hybrids
Acta Pharmaceutica·2024· 2 citedOpen Access
Hiding in plain sight: Optimizing topoisomerase IIα inhibitors into Hsp90β selective binders
European Journal of Medicinal Chemistry·2024· 2 citedOpen Access
Nanomolar inhibitor of the galectin-8 N-terminal domain binds via a non-canonical cation-π interaction
2024Open Access
First dual inhibitors of human topoisomerase IIα and Hsp90 C-terminal domain inhibit the growth of Ewing sarcoma in vitro and in vivo
Bioorganic Chemistry·2024· 1 citedOpen Access
Improved N-phenylpyrrolamide inhibitors of DNA gyrase as antibacterial agents for high-priority bacterial strains
European Journal of Medicinal Chemistry·2024· 3 citedOpen Access
Targeting N-Acetylglucosaminidase in Staphylococcus aureus with Iminosugar Inhibitors
Antibiotics·2024· 3 citedOpen Access
New Class of Hsp90 C-Terminal Domain Inhibitors with Anti-tumor Properties against Triple-Negative Breast Cancer
Journal of Medicinal Chemistry·2024· 12 citedOpen Access
Galectin-8N-Selective 4-Halophenylphthalazinone-Galactals Double π-Stack in a Unique Pocket
ACS Medicinal Chemistry Letters·2024· 2 citedOpen Access
Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria
European Journal of Medicinal Chemistry·2024· 4 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Lucíja Peterlin Mašič(31), D. Kikelj(29), Nace Zidar(21), Anamarija Zega(18), Janez Ilaš(16), Päivi Tammela(12), Stanislav Gobec(10), Didier Blanot(9), Martina Durcik(9), Marko Anderluh(8), Žiga Skok(8), Andreja Kovač(7), Michaela Barančoková(5), Roman Šink(5), Csaba Pál(5), Žiga Jakopin(4), Matjaž Brvar(4), Andréa Dessen(4), Jurij Trontelj(4), Cristina D. Cruz(4)